Beyond the Bottom Line

Panacea Healthcare Solutions

Welcome to Panacea’s podcast Beyond the Bottom Line: Let’s talk healthcare, finance, revenue cycle and compliance. Hosted by, Kevin Chmura, CEO of Panacea Healthcare Solutions. Whether you’re a healthcare executive, a financial professional, or simply curious about how these essential pieces of the healthcare puzzle fit together, you’re in the right place. Our goal is simple to give you actionable insights and expert perspectives that can help you optimize your operations and drive strategic growth.

Episodes

  1. 1D AGO

    Panacea Healthcare Solutions Acquires MedLearn Media

    #top .hr.hr-invisible.av-lp0dm4z0-ecbd31d22a8f649a0b55c5e684e7f0bc{ height:15px; } .avia-image-container.av-p7lzn9-ca64b9bb777573d554de4869a8146a76 img.avia_image{ box-shadow:none; } .avia-image-container.av-p7lzn9-ca64b9bb777573d554de4869a8146a76 .av-image-caption-overlay-center{ color:#ffffff; } Panacea Healthcare Solutions Acquires MedLearn Media With Host Kevin Chmura, CEO of Panacea Healthcare Solutions and Guest Angela Kornegor, CEO of MedLearn Media #top .hr.hr-invisible.av-46zq5v-ac3d0c5b9ed47d8f3785414847690b8c{ height:15px; } In this episode of Beyond the Bottom Line, Kevin Chmura is joined by MedLearn Media’s CEO, Angela Kornegor, to discuss Panacea and MedLearn’s shared history, in response to Panacea’s latest acquisition of MedLearn. Kevin and Angela dive into MedLearn’s trusted education brands which include MedLearn Publishing, RACmonitor and ICD10monitor and how combining forces completes the model of software, consulting and professional level education. They explore how this will give coding, HIM and compliance teams the tools, insights and accredited education needed to keep up with complex rules while protecting revenue and focusing on patient care. Episode transcript available below. Kevin Chmura Welcome to Beyond the Bottom Line. I’m your host, Kevin Chmura, CEO of Panacea Healthcare Solutions. After eight years apart, MedLearn Media has rejoined Panacea and I couldn’t be more pleased about that and I want to share why. Today I’m sitting down with Angela Kornegor, head of MedLearn, to talk about our shared history. MedLearn’s trusted Education brands which include MedLearn Publishing, RACmonitor and ICD10monitor and how combining our forces completes the model of software, consulting and professional level education. Our goal is simple, give coding, HIM and compliance teams the tools, insights and accredited education they need to keep up with complex rules while protecting revenue and focusing on patient care. So, Angela, welcome. Welcome to Panacea. Let me be the first to welcome you to Panacea. But I guess I should do this appropriately and welcome you back to Panacea. That’s probably the way to say it, right? Ours is an interesting. History, Panacea and MedLearn. And you’re probably more qualified to talk about it than I am because you, your time spanned both the time we were one company and the time we were and now we are again. So maybe I could ask you to just give me a couple of minutes on the history for everybody that’s listening. Angela Kornegor Yeah. Well, it’s been eight years. So, it’s been eight years since MedLearn was a part of Panacea, which was great. We were together for six years. At that time, we had MedLearn Publishing, RACmonitor, ICD10monitor, which we still have, but we didn’t have the depth of content in the digital format that we have now, eight years ago. Kevin Chmura Yeah, yeah, that’s it. And so a series of M&A moves brought the company together, brought the companies together, broke them apart. And then we found our way home to each other just a month or two ago. How long has it been? Angela Kornegor It’s been a long time, but it’s just officially a month ago. Kevin Chmura Deals are hard. Deals are hard and you were great during the deal. We have said this to each other that that the deals are hard because for so many people in a deal, the day of the closing is their last day. For you and me, it’s the beginning. We were involved in the rest of it as well. You were great. So, I’m looking forward to, you know, really working with you, not just to get the deal done. So, look for the Panacea customers who are pretty, pretty tight on what we do. I thought maybe you could give me a couple of minutes on. On MedLearn, generally catch everybody up. There are those who will remember MedLearn from the past and as you just stated, you’ve evolved greatly. So, you just if you give us a couple of minutes on what you’re doing today. Angela Kornegor Absolutely, absolutely. So again, we still have our three brands. So MedLearn Publishing, RACmonitor, ICD10monitor. Our goal there is to focus on trusted deep. Content that will help with regulatory rules and all the burdensome government changes that are going on left and right to help make sure that they can A) get accredited content because that’s what they need to keep their credentials up, but we want to help make sure that they’re continuing to be the hero at what they do because it’s not an easy job, it’s tough. And these complex rules make getting their revenue, focusing on patient care a challenge. And we want them focusing on patient care because that’s what impacts all of us. Kevin Chmura Yeah, yeah, it’s interesting. You know the coding HIM in in healthcare often called mid-rev cycle and it really is it’s the core. And when you think about it’s… The core is the handoff from the clinical to the financial and that handoff is so critical and we as an industry has not. We haven’t made it easy for the folks that are professionals in that space. We don’t need to have. I spent 30 years in the back end of the revenue cycle, certainly could get credentialed in different things, but was never required to unlike coders. So, what MedLearn does is so critical to that world and we’re excited to bring it to Panacea. I think that for us, where we live, several of our deliverables have clinical or coding or compliance orientation and we’ve been very proud of what we’ve done, especially in our coding audit space, bringing education back to our customers and our education is superior relative to competitors, but it’s still based on what we learned during that audit. We never had or I shouldn’t say until we came back together. We were really unable to extend that with professional level education and that’s what MedLearn is going to bring to our customers. So, we’re excited about doing that for our customers to be able to bring the subscription-based model that you have for some of your education, even the books, right? Yeah, coders still love books. Angela Kornegor Oh, they do. Kevin Chmura They do. And I have them on my desk as you know, I sort of leave them out as props today, but they. They’re super high quality and great. And without that, without that content available to people that we hadn’t had, we always had as complete a model as we could make it. And I really think that now at Panacea we’ve completed the model. So, we’re really excited about that. What’s exciting to you? Angela Kornegor There’s a few things. Definitely what we didn’t have, which now we’re going to have is a deeper level of expertise on pricing, price transparency that is going to give us more content and more well-rounded to be able to take our digital subscriptions and our accredited content to customers. So, we’re going to be able to get into deeper areas that we haven’t gotten into before, which are imperative. I cannot wait. Kevin Chmura Yeah, yeah, I’ll tell you what I’m excited about all of that. And two things. One, we’re bringing together two talented groups of people. So that just accrues benefits to the customers. So, it’s going to be wonderful to work with you, but you are not MedLearn alone, right? You’ve got a very talented group of people. You’ve got a big, big network of subject matter experts that you bring to the table as well. We’re excited to get to work with them. And then for me, what we have collectively is a very large customer base. We do business collectively with thousands of hospitals on an annualized basis of thousands of providers of all types to physician practices, clinics, ASCs and the Panacea deliverables really addressed most of those markets. The Medlearn content addresses all of them. So, what we have is a collectively large customer base that we can extend from software to consulting and now education. I don’t think there is another group out there that has what we have right now. So, what we pull together here is unique but makes so much sense. Almost obvious in a way, and I want to take credit for it and so should you. Except we used to be one company. Angela Kornegor Yes, exactly. Kevin Chmura And so homecoming of sort, and it makes a ton of sense. So we have some amazing things that we will be rolling out over the next year. I don’t know how long it, you know, there’s some immediate things that people will say. I think what for MedLearn customers, one thing that’s important to stress is the MedLearn brand name and delivery and approach and quality. It’s why we wanted to bring the companies together. We have no interest in changing that. So, if you’re a MedLearn customer out there, MedLearn will still be MedLearn. It will be a Panacea company. We’ll bring additional technology, a lot of resources, some sales, other things to the equation, but we intend to leave MedLearn alone otherwise and we think that’s really important. And but we also expect to benefit Panacea with that, so you’ll start to hear if you’re a Panacea customer, you’ll start to see an up leveling of our education and the quality of the information that we bring into our deliverable, which is exciting. So, we’re looking forward to that. What else can we tell everybody? Angela Kornegor I think we need to say what we’re going to bring to the table from a continuum of just, you know, from RACmonitor, ICD10monitor, Northern Publishing, such a wide expertise of CE credential content, digital subscriptions that are really affordable. We’re going to allow clients to be able to get access to everything, which is nice. You know, we’re, if they’re if they want multiple domains, multiple product lines, users, our goal is to make sure that we can offer this great trusted education that’s been around for over 30 years at a very affordable rate, becaus

    11 min
  2. 07/22/2025

    Medicaid Eligibility Under the One Big Beautiful Bill Act: Our Expert Breaks it Down

    #top .hr.hr-invisible.av-lp0dm4z0-ecbd31d22a8f649a0b55c5e684e7f0bc{ height:15px; } .avia-image-container.av-lp0ehts2-4651558e3615e819bf1aaa2b983f5b55 img.avia_image{ box-shadow:none; } .avia-image-container.av-lp0ehts2-4651558e3615e819bf1aaa2b983f5b55 .av-image-caption-overlay-center{ color:#ffffff; } Medicaid Eligibility Under the One Big Beautiful Bill Act: Our Expert Breaks it Down With Host Kevin Chmura, CEO of Panacea Healthcare Solutions and Guest Brian Herdman, Director, Financial Reimbursement Services, KA Consulting Division #top .hr.hr-invisible.av-46zq5v-ac3d0c5b9ed47d8f3785414847690b8c{ height:15px; } In this episode of Beyond the Bottom Line, Kevin Chmura is joined by policy expert Brian Herdman to discuss how the One Big Beautiful Bill Act is set to impact Medicaid eligibility, what this critical issue means for hospitals and healthcare providers, and how these changes can affect your bottom line. Kevin and Brian dive into not only what changes providers can expect to see right away, but also those changes which will be coming into play in the next few years, and how to best prepare before they happen. They also explore what challenges hospitals can expect to see as a result of this bill’s passage, as well as if there are any positives for healthcare systems or providers. Episode transcript available below. Kevin Chmura Hi, and welcome back to Beyond the Bottom Line, Panacea’s Podcast exploring the business and policy issues that matter most to healthcare organizations. I’m your host, Kevin Chmura, CEO of Panacea Healthcare Solutions. In this follow-up episode, we’ll continue our conversation with Panacea’s policy expert, Brian Herdman, about Medicaid funding, a critical issue for hospitals and healthcare providers, and take a closer look at how the latest developments in Congress and the administration could impact your bottom line. We’ll also revisit some of the practical steps you should be thinking about today to strengthen your organization’s financial position now that we’ve seen how these policy issues have unfolded. So Brian, welcome back to the podcast. Brian Herdman Great to be here. Kevin Chmura Great to have you back. So, Brian, the One Big Beautiful Bill Act, the OBBBA has now been signed into law and we did a podcast on this topic in March, at which point we were really looking at the versions of the bill that were being kicked around. We were really probably going more off of what we were seeing in the press, in the media, and less what we really knew. Now we’re getting a real look at it. You’ve had an opportunity to spend some time with the text and do your analysis. You are by far our best regulatory expert here at Panacea, so interested in in what you’re saying now, we can spend a lot of time going through the individual provisions as they relate to Medicaid and those things that will be deeply impactful. If we went through all of them, this would be a three hour podcast and I think we lose a lot of the audience. I thought maybe what would be better for everybody, given your expertise in this area? Probably crafting it a little to our target audience, which is probably mostly hospitals and health systems, wondering if you might just spend some time talking about those provisions and those elements that you’re paying the most attention to, the things that you think will be most impactful. And maybe we just take the conversation from there. Brian Herdman Sure. Sure, Kevin. So, you know, after all that back and forth and all those, you know, 4th of July deadline to get the bill passed and whatnot, there is a lot of, you know, what’s going to stay in, what’s not going to stay in between the House and Senate reconciliation process. And now that that has shook out, you know, as I’m looking at the Medicaid specific provisions, because I think that’s where the big change is going to be for our clients, on that Medicaid provisions, you know, there’s kind of two kind of two way, two sets of issues our clients are going to have to look at, you know, the things are going to affect which specific claims are going to be eligible for Medicaid and at what amount. And just generally speaking, the environment that the state, that the provider operates in the state with the state’s Medicaid program, what’s happening with FMAP, what’s happening with state directed payments and how is that going to all unfold? So as I’m looking at those two kind of main themes, you know, what’s happening like, you know, soon what’s happening soon-ish and then, you know, what’s kind of pushed out far ahead. And when I look at the things that are coming up soon, it’s not anything that’s like, you know, hair on fire, oh, my gosh, we have to do a lot of things differently. There was that immediate elimination of some moratorium on some things that would get you streamline applications into Medicaid. That’s going away. And, you know, there is that reduction in FMAP percentage to states when they have done that expansion. But, you know, on the margins, none of those things are going to be a dramatic change to how our clients, you know, get how many of those claims go through and how much they really get paid by the state. When you really start to see that happen is around January 2027. That’s when we’ll start to see a lot of big changes. And looking at those kind of changes right away our of the gate, that’s when you have the introduction of co-payments for enrollees that are at 100% or more of the federal poverty limit. That’s when that six-month redetermination process with that much tighter limits on retroactive coverage and work requirements, that’s coming into play in January of 2027. So, you know, up until then, I don’t think the kind of claims that get paid by Medicaid, there’s going to be a lot of change. But once you hit January 2027, all bets are off and you’re going to have to really have yourself organized. And then there’s those state directed payments. You know, that’s going to be much more difficult to foretell. There are a number of things that are going to affect how states are paid. There’s a couple of different dimensions that they’re tweaking the FMAP percentages on. But generally speaking, it’s that expansion population and how various undocumented beneficiaries are treated or allowed to be covered. Once states, you know, start to deal with the change in how that money is coming in from the feds, then that’s when you might start to see states start paying providers differently, whether it’s, you know, maybe a perhaps in margin on the erosion, on a on a payment or if you’re relying on those state directed funds to make up your margin, you know, you’re really going to be limited in what you can get from it. Kevin Chmura Okay, that’s excellent. Maybe double click on a few of these. I think it’s difficult for you and I as we sit here to comment on individual states, because depending on where people are listening in from, it could be very, very different scenarios. You and I are both in New Jersey right now. We don’t want to make this too New Jersey centric. A couple of things that really jumped out at me that I think that you touched on and just curious what your thoughts are. For instance, the work requirements for Medicaid, for those that are in the expansion population aged 19 to 64. That provision doesn’t start until December 31st, 2026, I believe, which is effectively January 1st, 2027. Is that right? Brian Herdman That is correct. So when I was talking about like in the short term, you know, the kinds of patients that you would expect to get paid and covered under Medicaid isn’t going to change a whole lot. But once you hit January 2027, that’s where on the margins there’s going to be some very difficult cases to get through. Kevin Chmura Right. Likely then flowing out and up to another year later as things flow into state budgets as well. So that might not be directly budgetary impact. That’s a that’s a process issue, one that matters. The other process issue that jumped out at me as I think about our eligibility enrollment business at Panacea, is the increased eligibility redeterminations down to six months from a year. Any thoughts on that? Brian Herdman Well, that’s, you know, that’s going to challenge, you know, your systems and how you’re usually interacting with patients. You know, when it’s when it’s a year in between these cycles, you are often dealing with someone who if they had an encounter that was a that was a spate of illness that got them on to Medicaid and had some follow-up care, you still might be in touch with them six months down the road, whereas twelve months down the road they might not need any care. And so in that case, you’re going to you’re going to be much more interested in making sure that care continues and you’re going to have to be more engaged with your patients. As you look at what services those patients that are trailing off and receiving, and how you reach out to them to make sure that their coverage continues without a break. Kevin Chmura Yeah, that’s great. So the other thing to think about is the other side of a of an application. So at a hospital you work with a patient, you have them fill out the application, you gather up their documentation that then goes to a county office who just doubled up the amount of work that is potentially flowing through and probably not one-for-one doubling, because you’re right, if a patient doesn’t need care six months out, they may not get that redetermination. But the good chance they’re still in an episode of care and need to do that and the depending on where you are, those county offices can be well back-logged to begin with. Brian Herdman And now they’re looking at the work requirement portion of it, too. So that’s ano

    15 min
  3. 07/14/2025

    Introducing RevenueRx™: A Comprehensive Drug Assistance Program for Hospitals

    #top .hr.hr-invisible.av-lp0dm4z0-ecbd31d22a8f649a0b55c5e684e7f0bc{ height:15px; } .avia-image-container.av-lp0ehts2-faeb520a9aedcb001000e703b2971d40 img.avia_image{ box-shadow:none; } .avia-image-container.av-lp0ehts2-faeb520a9aedcb001000e703b2971d40 .av-image-caption-overlay-center{ color:#ffffff; } Unlocking Access: How RevenueRx Transforms Drug Assistance for Hospitals With Host Kevin Chmura, CEO of Panacea Healthcare Solutions and Guest BreAnn Meadows, President, Revenue Integrity Services #top .hr.hr-invisible.av-46zq5v-ac3d0c5b9ed47d8f3785414847690b8c{ height:15px; } In this episode of Beyond the Bottom Line, Kevin Chmura is joined by BreAnn Meadows to discuss Panacea’s latest healthcare solution: RevenueRx: Drug Assistance Program designed to help hospitals streamline access to free drugs, co-pay assistance, and charitable foundation support programs. Kevin and Bre delve into this new service, what it offers to hospitals, why the solution is being introduced now, and what sets RevenueRx apart from other programs. They also share specific examples of how it can deliver measurable benefits and meaningful impact for your healthcare organization. Episode transcript available below. Kevin Chmura Welcome to Beyond the Bottom Line: Let’s talk healthcare, finance, revenue cycle and compliance. I’m your host, Kevin Chmura, CEO of Panacea Healthcare Solutions. Whether you’re a healthcare executive, a finance professional, or simply curious about how these essential pieces of the healthcare puzzle fit together, you’re in the right place. The goal is simple: Give you actionable insights and expert perspectives that can help you optimize your operations and drive strategic growth. In today’s episode, we’re talking about a topic that’s becoming a real game changer for hospitals and health systems, patient drug assistance. Joining me is BreAnn Meadows, president of Revenue Integrity Services here at Panacea Healthcare Solutions. Bre and her team just launched RevenueRx, a service that’s helping hospitals streamline access to free drugs, co-pay assistance and charitable foundation support programs. Welcome, Bre. Bre Meadows Thank you. Kevin Chmura So let’s start with the basics. What is RevenueRx? And it’s probably a good place to start. And why did we decide to launch this at Panacea now? Bre Meadows So RevenueRx is a comprehensive tech enabled service that helps hospitals and cancer centers manage the manufacturer-sponsored drug programs. And then also the foundation assistance. So, as you said, we do include services based around the manufacturer free drug programs, the co-pay assistance programs, and the charitable foundation funding we launched RevenueRx because hospitals are still continuing to face growing pressures. The cost of drugs just continues to go up, and the payer policies get more and more difficult to manage, along with patients out-of-pocket and coverage determinations always being really challenging. So there’s a lot of roadblocks when a patient gets a diagnosis where they have to go to a cancer or infusion center to start one of these treatments. And the reason we launched this program is to really help hospitals clear those roadblocks so patients can get access to care without being financially destroyed by their diagnosis. So it’s a great program that really benefits the facility financially as well as the patient, to give them access to these drugs that could save their life. Kevin Chmura Wow. So real win/win, right? You’ve got better access for the patients and operational relief and revenue, most importantly, for hospitals and health systems, which is great. It’s always nice when everybody gets a win out of it. So great rundown on the on the benefits of it. But can you walk us through what is the actual deliverable of RevenueRx? Bre Meadows Sure. So RevenueRx is almost set up a little bit differently than some other services that are out there that even though we’re technical, we still really focus on the service and really working closely with the organization and their patients. So what we manage is everything, soup-to-nuts, starting with the application process. So we do all the screening of patients looking for all the programs that the patient could qualify for, completing the application and making sure the patients get approved for not just the primary drug that they may be receiving for that service, but any and all drugs to minimize their out-of-pocket as much as possible. The second piece that we do is making sure that after the application is approved, that everything gets followed through on behalf of the patient and the organization. So when we talk about “free drug,” we handle the ordering and try to get everything ordered as prospectively as possible. And we could talk a little bit more in depth about the advantages of that and billing compliance, but making sure that also the patient has confidence as they’re coming in for these visits. They know that we’ve taken care of it. They know their drug is sitting there waiting for them and that they’re not going to be getting a bill after they leave the center. And then the third part is on the co-pay and foundation programs. Again, after a patient is approved, we do all the tracking to make sure that the funds get loaded for the patient and then make it on to the hospital account for them. So we take all the steps out. There’s nothing for the patient or the organization to do except, you know, look at the accounts and we’ll highlight, you know, the dollars that got paid. But we take care of every single step in between so that we’re 100% sure that every approved application gets the maximum value. Kevin Chmura Wow. That’s impressive. We know from our Medicaid eligibility business here at Panacea that that’s pretty comprehensive but also single application typically going to one place, county office with the a fair amount of follow up. I imagine the level of tracking and compliance for this is critical, especially with the changing landscape in healthcare. Bre Meadows Yeah, I mean, with patient drug assistance programs, getting the application approved is really the easy part. What’s difficult is following all the steps afterwards to make sure that you can maximize the value of that approval. And we see with organizations that either are running their own internal program, or maybe using a limited partnership with an outside business partner, they may not be maximizing everything. There’s just so many steps to do and so much to cover. And having a comprehensive program where you’re really focused on that ensures that you’re going to get 100% of that value. Kevin Chmura So, you and I have been in operations for a long time. And so it’s always helpful for me, and maybe for the audience, would be maybe taking us through a real world example and kind of what the impact of RevenueRx would be for a hospital. Bre Meadows Sure. That’s a great question. And it really is eye opening to kind of walk through an example. So the way it works is, let’s say Kevin Chmura, unfortunately has a diagnosis where he needs to get a high cost drug that is going to be administered in a hospital infusion center. And your treatment plan says that you are going to get six treatments over the next six months. So, one treatment a month. And then you find out that this drug costs $15,000 a dose. Now, you work, you have insurance, but you have a deductible, and you may have a large portion of coinsurance to pay. So, you know, you get a call from patient access and they start to tell you what your out-of-pocket is going to be and start to ask you how you want to pay for that. And most patients are going to find those amounts really shocking. So what we’re doing is trying to grab those, understand the patient’s insurance coverage and how much out-of-pocket. So say out of this $15,000 infusion, every time you come in, you have a $2500 obligation to pay towards this drug. We will immediately start going through the co-pay and foundation opportunities to get it covered, and then inform you to let you know. So every $2500 payment that you would have had to make for each of these six treatments, we’re hoping to get it down to close to zero. Now, there are other opportunities. If you are a patient that doesn’t qualify for a copay program for whatever reason, we still want to eliminate your obligation to pay for that drug. And the way we do that is to start an application for free drug and demonstrate the financial burden that you might have and get that drug shipped for free, which then eliminates the hospital’s acquisition cost as well as 100% of any out-of-pocket that you may have had for that drug. Kevin Chmura Wow. It would be amazing to get it to zero, right, for any patient. Bre Meadows The only reason we can’t get some of them to zero is because, unfortunately, a lot of these programs won’t cover administration fees, but those are very small and the drug is the main thing that we need to worry about with these bills. Kevin Chmura Yeah. Yeah. So drug manufacturer assistance programs are not necessarily new. They’ve been around for a bit. And I would imagine that most hospitals are, you know, engaged in some level of activity, trying to avail their patients of the opportunities there. But so how is RevenueRx really different from what you see hospitals are doing today? Bre Meadows So the good thing is, I do agree, when we talk to hospitals, there are generally some people who are aware of these programs. They typically tend to be some pharmacy staff, who are not really directly related with a patient or what’s going on with their bills, or maybe social work or patient access. And what we find is people with their heart in the right place trying to do as much as they can for the patient, but not being able to compl

    14 min
  4. 05/14/2025

    Price Transparency Enforcement Ramps Up: What Hospitals Need to Know

    #top .hr.hr-invisible.av-lp0dm4z0-ecbd31d22a8f649a0b55c5e684e7f0bc{ height:15px; } .avia-image-container.av-lp0ehts2-55a778b70d59cdcd02900972dfb676ba img.avia_image{ box-shadow:none; } .avia-image-container.av-lp0ehts2-55a778b70d59cdcd02900972dfb676ba .av-image-caption-overlay-center{ color:#ffffff; } Price Transparency Enforcement Ramps Up: What Hospitals Need to Know With Host Kevin Chmura, CEO of Panacea Healthcare Solutions and Guest Govi Goyal, President, Financial Services #top .hr.hr-invisible.av-46zq5v-ac3d0c5b9ed47d8f3785414847690b8c{ height:15px; } In this episode of Beyond the Bottom Line, host Kevin Chmura and guest Govi Goyal dive into the latest developments in hospital price transparency following President Trump’s February 25th executive order. The order directed federal agencies to rapidly ramp up enforcement of existing transparency regulations and explore new ways to ensure compliance—with a clear 90-day deadline. Kevin and Govi break down what this means for healthcare organizations, including the surge in CMS enforcement activity, the potential for updated guidance on standardization and data reporting, and how hospitals can prepare. Drawing on recent client experiences and industry trends, the conversation offers timely insights for revenue cycle, compliance, and pricing leaders navigating the shifting transparency landscape. Episode transcript available below. Kevin: Hi, and welcome to the episode Panacea’s podcast Beyond the Bottom Line. Let’s talk healthcare, finance, revenue cycle and compliance. I’m your host, Kevin Chmura, CEO of Panacea Healthcare Solutions. Today, we’re going to be doing a follow-up to a podcast we released in February highlighting kind of the rapid reaction to an executive order signed by President Trump, doubling down on price transparency enforcement. It’s been a little bit of time since then, and we thought it would be a good time to bring back our guest from that episode, Govi Goyal, who is President of our Financial Services division and leads our price transparency practices and really a national nationally recognized expert on all topics price transparency. To kind of give us an update on how that’s translating out into the market and what we’re seeing. So first, let me welcome Govi. Thanks for coming back. Govi: Thanks Kevin. Good morning. Kevin: So, maybe just set it up for the listeners, if you didn’t get a chance to listen to our first podcast, you can find that on our website. Also, you can find those on Apple Podcasts as well. If you want to go back and subscribe to Beyond the Bottom Line. But I’ll just I’ll do a quick rundown of why we did that podcast and then maybe stick to what we’re seeing. So in that we talked about ,that on February 25th, President Trump signed a new executive order. And what that did was it specifically instructed the Secretaries of Treasury, Labor and Health and Human Services to rapidly implement actions to enforce the price transparency regulations from the original executive order, EO 13877, and this was an important piece, within 90 days. So he put the word rapidly in there. But then he also defined what rapidly was, which is within 90 days. I want to see enforcement of the existing regulations and also instructed them to, if you can find new ways to enforce regulations. It’s been about 75 days since then, and we are starting to see some of that executive order filter out into the marketplace. And so, you know, just in our internal discussions, we’ve talked a little bit about what we’re seeing. So Govi, maybe I won’t oversell it. Maybe you could just tell us what are you hearing out in the market? What are we seeing? What are what our customers and prospects calling us, telling us, like, what? What’s out there right now? Govi: Yeah, slowly. And I think the executive order is a good place to start because that’s what’s really triggering a lot of the activity that we’re seeing. And you hit the nail on the head. It’s really a two-pronged approach. There’s the increased enforcement, which we’re definitely seeing and we’re going to jump into. But then there’s a second part, which is around actually improving the price transparency requirements. And so it’ll be interesting to see. We’ve got, as you mentioned, just about 16 days left here before the 90 days is up. As part of the executive order, there’s language in there that states within 90 days we should see either updated guidance or proposed regulatory action on two different things. One is around ensuring pricing information is more standardized and is easily comparable across hospital health plans, which does a little, I’m really interested is hear and see what that guidance might be, because back in 2024, July of 2024, it was required for all hospitals to comply with a standardized CMS template. And the primary reason for that is to get to more apples-to-apples comparisons so you wouldn’t accidentally compare like a case rate to a per diem or a PPO to HMO. So we’ll see what other, you know, further guidance or regulatory action is going to be coming up for hospitals or even health plans to comply with. The other piece is more around seeing any guidance or regulatory action in terms of reporting a complete, accurate and meaningful data. And that’s more around enforcement policies. And so in terms of enforcement, we are seeing an increase in the volume of, we call them CMS love letters here. Really what they are violation notices. There’s a website, https://data.cms.gov/ that you can go to, I actually just went to it earlier this week where you can see a list of all the difference enforcement actions. So you can see all the hospitals that either received a penalty or a violation notice or a corrective action plan. And there’s definitely a trend. There’s an upward trend to see more activity in 2023 and 2024, unfortunately, it’s not updated for 2025. If it was, you would definitely see that spike occurring almost immediately after February 25th, with the executive order. I’ve been drawing upon a lot of experience, personal experience, industry experience. We have a lot of hospital health systems that have approached us and asking for our advice because they’ve received the letter from CMS. So we’re definitely, it’s, I think it’s safe to presume that that increase is due to the Trump administration executive order. Kevin: Yeah, that’s we, letters were somewhat of a rare occurrence for at least you know our customer base as we’ve always talked about it but we agreed, I think the team is talking about an uptick in them. Any insights into the content. Right? Just getting a letter is one thing, but what are what are people being told by CMS? Govi: Yeah. So for now, what we’re seeing is a lot more related to the accessibility of the files. And I think what CMS is doing is they’re following a phased approach. So for now, what CMS is doing is they’re making sure that all the machine readable files out there are accessible and there’s two primarily two or three things that hospitals are getting dinged on. One of them is the text file requirement. So all hospitals that are required to comply with hospital price transparency, they must include a text file in the root folder of their website. And so this file, it needs to contain information like the hospital’s location, the URL of the webpage that’s hosting a single file, a direct link to the MRF, and I think a the hospital point of contact information. So pretty much those standard five things, there’s a lot of instruction out there that CMS has put on their website, but unfortunately we’re seeing a lot of hospitals that don’t have the text file up at all. They’re completely non-compliant with it. Or they have the text file up, but they have issues that we, you know, the layperson would consider very nitpicky. Maybe there’s a typo. Maybe their, the MRF URL is not pointing directly to the MRF, it’s pointing to the website instead. Even if it’s those small areas that deviate from the instruction of CMS, you will get a warning letter or Violation Notice on that. Just to give you an example of how nitpicky it could be, we were working with a health system that had, they had pricing transparency listed on the footer of the websites. So instead you should have price transparency, not pricing so that that word differential there was enough to get them a violation notice. So it needs to be 100% correct. That’s what we’re seeing today. There’s, you know, to talk about what the phased approach will be. We really think the next phase is going to be the CMS validator. So I think what CMS is trying to do is they’re trying to make sure all the files are accessible so that they can do some automation, they can send out the bots to grab the files, and then the next phase will be running it through the CMS validator, see if you’re compliant from that perspective. Kevin: Yeah. So maybe, maybe one way to think about it is that the, these initial letters are probably a combination of kind of a quick win by CMS to say, hey, look, we’re stepping up our enforcement and these people use the word pricing instead of price and that’s a violation. But yeah, they’re trying to line up the data so that they can take it and run the validator through, run it through the validator, which will be an entirely different level because I think the, you know, things like the text file, those are the regulations that are spelled out maybe relatively easy to fix, start to get into some of what the validator may find as flaws with your machine readable file. Maybe not so easy to fix. You think that’s fair? Govi: Yes, I think so. And I, it’s giving hospitals a little bit of breathing room to, kind of, you know, a heads up that at some point, once we get through the, once the message

    19 min
  5. 03/28/2025

    Potential Impacts of Medicaid Funding Cuts on Providers

    #top .hr.hr-invisible.av-lp0dm4z0-ecbd31d22a8f649a0b55c5e684e7f0bc{ height:15px; } .avia-image-container.av-lp0ehts2-3b5d951dc6aac5f8f0d10ade4fb7c753 img.avia_image{ box-shadow:none; } .avia-image-container.av-lp0ehts2-3b5d951dc6aac5f8f0d10ade4fb7c753 .av-image-caption-overlay-center{ color:#ffffff; } Potential Impacts of Medicaid Funding Cuts on Providers With Host Kevin Chmura, CEO of Panacea Healthcare Solutions and Guest Brian Herdman, Director Financial Reimbursement Services #top .hr.hr-invisible.av-46zq5v-ac3d0c5b9ed47d8f3785414847690b8c{ height:15px; } In this episode of Beyond the Bottom Line, Let’s Talk Healthcare Finance, Revenue Cycle and Compliance, host Kevin Chmura, CEO of Panacea, is joined by Brian Herdman, Panacea’s Director of Financial Reimbursement Services, as they discuss the House Republican budget plan’s mandate to reduce spending from a variety of programs, including Medicaid With cuts of approximately $880 billion in funding over the next ten years, find out what programs are likely to see a reduction. Episode transcript available below. Kevin: Hi and welcome to this episode of Panacea’s new podcast Beyond the Bottom Line. I’m your host, Kevin Chmura, CEO of Panacea Healthcare Solutions. In today’s episode, we’ll be discussing a very important and timely topic for every healthcare provider, particularly hospitals, and that’s Medicaid funding and potential changes proposed by the new Congress and endorsed by the administration. We’ll also cover some practical steps you can take today that will help regardless of which of these proposals are adopted, or even if none of them are. I’m joined today by Brian Herdman, Panacea’s Director of Financial Reimbursement Services. In addition to Brian’s day job at Panacea, helping hospitals maximize financial performance, he also leads our efforts to monitor the regulatory environment and position Panacea to best help our customers navigate those waters. Brian, welcome to the show. Brian: Thank you, Kevin. Glad to be here. Kevin: Cool. So a lot going on in the world right now, a lot going on in healthcare. There always is, but whenever there’s a changeover in administration and a new Congress coming in, there’s always a lot going on. So particularly wanted to dive in today, the House Republican budget plan, which was endorsed by President Trump in February, includes cutting approximately $880 billion of funding over the next 10 years from a variety of programs. To put that into perspective, for anybody listening in 2023, which is the most recent full year data we have across the entire country, we spent 170, I’m sorry, $872 billion in Medicaid funding. So in other words, we’re eliminating an entire year’s worth of funding over the next 10 years, or roughly 10%. But given the rise in health Medicaid spending since the onset of the ACA, the number’s actually much bigger than 10%, because we only reached 872 billion in 2023. It was much lower than that over the years prior to that. So what I’m getting at, it’s a really big number. It’s a really big number that’s potentially coming out. There are some estimates for some extended proposals that take that number into the trillions, though perhaps, maybe unlikely. So Brian? I know you. You immerse yourself in this as part of your part-time job with us. And so I know you’ve looked at this and you’re advising our customers through it. What are some of the key things that you’re paying attention to in the proposals that are out there right now? Brian: Hey, Kevin. So as I’m looking at this proposal, if you look at the actual legislative text you mentioned, there’s not really a whole lot to go off of, just a mandate to reduce spending. So there’s no real specific policy behind it. So from there you have to look at what has been proposed in the past and what people are complaining about on the campaign trail and other things. So when you look at these proposals, you know, one thing that bumps out right away is tweaking the dial on the federal match that the federal government pays out the states. This could be program specific. You know the Medicaid expansion population gets a much richer match from the feds, so that might be something that gets reduced down. Or there could be across the board decreases in that federal match. One thing that comes up a lot is block grants. Possibly converting those Medicaid payments into per capita amount so that those are more inflation adjusted from the get-go. And they’re not really going to be determined by how the state spends that money. And even there’s some other piles of money that the feds do matching on that could be eliminated there. Nearly every state has some kind of provider tax that brings money into their state Medicaid program that is matched by federal dollars. Some of this is small and some of this is significant. In some states, it’s very significant, with hundreds of millions of dollars moved around and appropriated back to hospitals, nursing home, etc. With matching dollars from these programs, so any of them are ripe for reduction. And it could be a little bit of this could be a little bit of that, but there’s a lot for the Congress to choose from. Kevin: Yeah, totally. And when you get into entitlement spending, it becomes highly politicized and very difficult to enact every proposal and it’s due to the nature of especially the Medicaid program, which is, you know, as we all know, administered by the states. And so highlighting something you said, it you know anyone change will not have the same impact in every state it’ll be outsized depending on options that the states have chosen. But I think it’s probably fair to say, and I’m sure you’d agree, that any reduction in funding is going to have an impact on, especially hospital financials. And you know, may be worse for some states, may be worse for some types of hospitals or where they rely on their funding. So you know, so with the undoubted lead to this, it lead into financial hardship on providers. What are some of the things that you’re going to be kind of advising our customers to be looking out for in the next couple of years. Brian: You know one thing in particular is if that Medicaid expansion cohort, if, if the matching funds really comes down on that, that side of the Ledger, states will have the opportunity to just discontinue that entirely. And in that case, we’re talking about entire cohorts of patients that just won’t be covered by their state Medicaid program. And some of the studies have put that number up to 20 million people. If they start moving around with the match percentage or some of the other programs, then you’re starting to get into marginal impacts and it’s going to be state-to-state on how they handle their rates for hospital services or physician services and what kind of special programs they might do to support safety net hospitals. If some of these match, some of this matching money goes away there is going to be a much smaller pot for the state to allocate in its rate setting process and as a result of that, it’s gonna depend on where that rate hit happens. But safe to say that with the breadth of services the hospital provides, they’re gonna be feeling it in some way or another. Kevin: Wow, so if I’m hearing you, you’re saying that what we could have is almost a triple effect of less people eligible for programs, a reduction in what the programs cover and then probably coinciding with all of that, a general reduction in reimbursement for those things that are still covered and for those people that are still covered. Is that right? Brian: Oh yeah, that’s definitely the case. You know, if you take money away, it’s going to have to come in from somewhere else. Some states might be willing to bring in other general funds, but that’s going to affect other initiatives they might want to do in other areas, whether it’s, you know, supporting schools or other kind of property tax initiatives. So, there’s going to be a lot of tough, tough decisions around that. Kevin: Very tough and tough this is a vulnerable population of people that that are covered by Medicaid and often being serviced by an equally vulnerable group of providers that do not live on healthy margins to fund all their programs. These are often rural or safety net that that hospitals that are that are heavily reliant on this funding so, so scary time. So then let’s switch to perhaps something a little bit more practical. We’re not trying to scare everybody, but there’s a lot happening there. So if I’m a hospital administrator today, if I’m a Chief Financial Officer, revenue cycle VP. Any advice that you could give me on what I could be doing now to prepare? Brian: Sure. Well, I mean, the main thing that I see is, you know, let’s look at your eligibility program and evaluate, you know, how strong and how much you’re really digging to make sure that your documentation and your relationships with patients are bringing in the right information you need to act and get them in the right program. It may be the case that there’s some programs that have scant criteria to join, and those might be the first programs to go, so if you’re not, don’t have a shop that is really getting all that information in and you’re relying on, you know, an easy infra program, you might be in trouble and you might need to dig a little bit deeper and make sure you can find a more appropriate program for that patient that’s going to be continuing. And you know, there’s always been this cost share concept in in healthcare with hospitals and whatnot. You know, trying to get more money from commercial payers to make up the difference so you know, let’s make sure that those commercial rates are doing as much lift as they can to make up

    13 min
  6. 02/27/2025

    Rapid Response: President Trump Reintroduces Price Transparency with New Executive Order

    #top .hr.hr-invisible.av-lp0dm4z0-ecbd31d22a8f649a0b55c5e684e7f0bc{ height:15px; } .avia-image-container.av-lp0ehts2-2feccf4627f137cb1e356cb0c18d2ff6 img.avia_image{ box-shadow:none; } .avia-image-container.av-lp0ehts2-2feccf4627f137cb1e356cb0c18d2ff6 .av-image-caption-overlay-center{ color:#ffffff; } President Trump Reintroduces Price Transparency with New Executive Order With Kevin Chmura, CEO of Panacea Healthcare Solutions #top .hr.hr-invisible.av-46zq5v-ac3d0c5b9ed47d8f3785414847690b8c{ height:15px; } In the first ever episode of Beyond the Bottom Line, we take a look at a new Executive Order from President Trump, Fulfilling the Promise of Radical Transparency, signed February 25th, 2025. Kevin Chmura, CEO of Panacea Healthcare Solutions and our host, is joined by Govi Goyal, President of Panacea’s Financial Services Division, to discuss this new enforcement to Hospital Price Transparency regulations. Listen in as they break down what is new in this Executive Order, what enforcement measures are now in place, and what steps healthcare organizations should take to ensure compliance. In addition, hear what Govi Goyal predicts for the future of Price Transparency. #top .hr.hr-invisible.av-2re35v-5ad9607ceb2e766cfd1618fc64fea115{ height:15px; } #top .hr.hr-invisible.av-m7tjcqjy-c6521239b29024472a577a9284623ae0{ height:15px; } Episode transcript available below. #top .hr.hr-invisible.av-m7tj99tp-2ca3c06c01668ad3ffcef2515598e6a0{ height:30px; } Kevin: Welcome to the inaugural episode of Panacea’s new podcast Beyond the Bottom Line. Let’s talk healthcare, finance, revenue cycle and compliance. I’m your host, Kevin Chmura, CEO of Panacea Healthcare Solutions. Whether you’re a healthcare executive, a financial professional, or simply curious about how these essential pieces of the healthcare puzzle fit together, you’re in the right place. Our goal is simple to give you actionable insights and expert perspectives that can help you optimize your operations and drive strategic growth. In this episode, I’m joined by Govi Goyal, Panacea’s President of our Financial Services Division. Financial Services Division at Panacea handles our strategic pricing and Price Transparency products and services. Govi is a nationally recognized expert on Price Transparency topics, having really been a leader since the first regulations were released by CMS. And we are providing a little bit of rapid reaction to a new executive order that was signed by the President yesterday and want to just give some initial feedback, some observations, some client interactions that we’re having, and just catch everybody up on what’s going on in as close to real time as we can. So first, let me welcome Govi to the show. Welcome, Govi. Govi: Hi Kevin. Kevin: Good to talk to you as always. So as I mentioned, we have a new executive order signed by President Trump. It was less than 24 hours ago as we record this right now. Interesting, and but probably not surprising to those of us that have been immersed in this, I’m sure not a surprise to you Govi, in the first Trump administration, the president and his team showed a real commitment to Price Transparency. Really believing it was a way to help lower healthcare costs for individuals and employers to buy insurance. Many people will likely recall that it was President Trump that signed the No Surprises Act in 2020, which gave way to Good Faith Estimates as another element of Price Transparency. He always showed a strong commitment to Machine Readable Files and to consumer displays for comparative shopping. So it probably shouldn’t be a surprise to any of us that within a month of taking office or so, he has signed an executive order, really doubling down on some of the work he did in his first administration. I’m just going to for the audience’s benefit, in case you haven’t seen this yet, you’re hearing this for the first time. I’m going to just read one section of this. Just bear with me. It’ll only take a second. And then I’m just going to ask Govi for his reaction to it. So Section 3 of the executive order, signed on February 25th, 2025, is entitled Fulfilling the Promise of Radical Transparency. I love the adjective in there, radical transparency, and it states this: the Secretary of the Treasury, the Secretary of Labor and the Secretary of Health and Human Services shall take all necessary and appropriate action to rapidly implement and enforce the healthcare Price Transparency regulations issued pursuant to Executive Order 13877, including within 90 days of the date of this order. Action to: A. Require the disclosure of actual prices of items and services, not estimates; B. Issued updated guidance or proposed regulatory action ensuring price information is standardized and easily comparable across hospitals and health plans, and; C. Issued guidance or proposed regulatory action updating enforcement policies designed to ensure compliance with the transparent reporting of complete, accurate and meaningful data. That’s the meat of the EO. The preamble before that, what’s after that is generally general provisions and I have my own thoughts on it, but they will pale in terms of their importance to yours Govi. So Govi just it’s as new. We’re seeing it for the first time. Just curious if you could give me your initial reaction to what we’re seeing here. Govi: Yeah, absolutely. So, you know, for a brief moment, the spotlight is taken off DOGE and away from all these federal workers who possibly might lose their jobs, and it was on Price Transparency. And a lot of this is not surprising. It’s a bipartisan issue. So the Republicans want it. The Democrats want it. So I think, you know, a lot of what’s in here confirms that Price Transparency is here to stay. It’s also going to continue to evolve, and I think while this particular executive order is a lot more about enforcement, which has been lagging, there has been enforcement and we have seen some improvement in compliance. But there’s still a lot of gaps in the data, there’s errors. And I think it’s been almost a year since the last hospital received a Civil Monetary Penalty. This executive order doesn’t necessarily have what I would say, like new policies or new requirements that providers need to immediately start incorporating or applying in their process. That should be a relief for many hospitals. Those who have invested significant time, costs and energy, especially on the January 1st changes we had this year with the Machine Readable Files of estimate allowed amount of pharmacy and modifiers and then all the changes that happened in 2024 with the standardized CMS template. Kevin, you did touch upon I think I agree that is the perhaps the most important part. Section 3 taken from the executive order, especially that first line item where it talks about departments, and it’s referring to HHS, Treasury and so forth, where hospital payers need to disclose the actual prices, you know, not estimates, including pursuant drugs. So in order for Price Transparency to really achieve the goals that it’s trying to achieve, which is to make healthcare more affordable, provide patients with informed decisions, increase competition. Three things need to happen. The files and data needs to be accessible, which I think we’ve come a long way. We’ve removed a lot of barriers to have the text file, the links are required in the footer of hospital websites. They need to be complete. So you can’t have significant gaps, things missing, and then they need to be need to be accurate. And if only they’re accurate, that’s the only way consumers will be able to shop around accurately. That’s one way we will be able to get to more standardize, less disparity in pricing across some across different organizations or healthcare organizations. So I think that is an important call out because a lot of hospitals, health systems have been leaning more towards using historical claims and payments data to arrive at their negotiated rates, which is which is okay to do for the estimated allowed amount, but in terms of getting to your standard negotiated rate, that should really be taken from your actual payer contracts to be as accurate as possible. Kevin: Yeah, that’s something that we for reference for those listening, at Panacea, we work with a few hundred hospitals across the country to help with their compliance needs relative to Machine Readable Files and other elements of Price Transparency. And so we, you know, we live in the world of accessible complete and accurate as Govi put out there and each has its one or two of them are simple, complete and accurate can be complicated. As we learned with the January 1st compliance deadline, with the inclusion of estimated allowed amount. So one of the things that strikes me about this, Govi, and just wondering what you think about it, is really B and C both talk about issuing updated guidance on proposed regulatory action, and they both say that same thing. They don’t say we’re going to update the regulation and the rules. We’re not going to add an additional field. This is very much to me enforcement oriented. Would you agree? Govi: Yes, I would agree. I think likely the scenario we had this year and last year was hospitals were getting a little bit of a break. You know, there was it was such a big change to go from the 2021 requirements of Price Transparency to all of a sudden jump to the 2024 and 2025. So the thought process was give a little bit time breathing room for hospitals to respond and apply those changes. Maybe with the direction we’re seeing of this executive order is, okay, the time’s up, it’s time to get more serious about enforcement and potentially, you know, we could see an evolution in the way CMS is doing their review is to confirm compliance, potentially gatherin

    23 min

Ratings & Reviews

5
out of 5
4 Ratings

About

Welcome to Panacea’s podcast Beyond the Bottom Line: Let’s talk healthcare, finance, revenue cycle and compliance. Hosted by, Kevin Chmura, CEO of Panacea Healthcare Solutions. Whether you’re a healthcare executive, a financial professional, or simply curious about how these essential pieces of the healthcare puzzle fit together, you’re in the right place. Our goal is simple to give you actionable insights and expert perspectives that can help you optimize your operations and drive strategic growth.